News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Client Alert March 3, 2026
When Should Companies Disclose Drug Safety Risks?
Our lawyers discuss a recent ruling highlighting when companies should disclose drug safety risks.
Firm News March 3, 2026
Gibson Dunn Advises Gyre Therapeutics on Its Acquisition of Cullgen
Gibson Dunn is advising Gyre Therapeutics, Inc., an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, on its acquisition of Cullgen Inc.
Firm News February 17, 2026
Gibson Dunn Advised Galecto on Public Offering of Common Stock
Gibson Dunn advised Galecto, Inc. on its public offering of common stock, which generated aggregate gross proceeds to the company of approximately $316 million.
Firm News February 4, 2026
Advised BioCryst Pharmaceuticals on $400 Million Debt Financing for Acquisition of Astria Therapeutics
Gibson Dunn represented BioCryst Pharmaceuticals, Inc. in connection with a $400 million senior secured term loan facility to finance the acquisition of Astria Therapeutics, Inc.
Firm News January 14, 2026
Gibson Dunn Advises Immedica Pharma on Acquisition of Neurocrine Group
Gibson Dunn is advising Immedica Pharma AB on the acquisition of Neurocrine Group Limited.
Client Alert January 12, 2026
Life Sciences 2026 Outlook
The life sciences industry enters 2026 with a constructive set of tailwinds, following a second half of 2025 in which dealmaking activity showed clearer signs of normalization after a prolonged slowdown. While risks remain, particularly around geopolitics, trade policy, and regulatory priorities, the overall setup for 2026 is cautiously constructive, with improved visibility into execution pathways for well-positioned assets and platforms.
Firm News January 12, 2026
Gibson Dunn Represented Arrowhead Pharmaceuticals on Concurrent Public Offerings of Convertible Notes, Common Stock, and Pre-Funded Warrants and Related Capped Call Transactions
Gibson Dunn represented Arrowhead Pharmaceuticals, Inc. on concurrent public offerings of convertible notes, common stock, and pre-funded warrants to purchase common stock for aggregate gross proceeds of $930 million to Arrowhead and capped call transactions relating to the convertible notes.
Firm News January 8, 2026
Gibson Dunn Advises Jefferies LLC on Ventyx Biosciences’ Approximately $1.2 Billion Sale to Eli Lilly and Company
Gibson Dunn is advising Jefferies LLC as lead financial advisor to Ventyx Biosciences, Inc. on Ventyx Biosciences’ approximately $1.2 billion sale to Eli Lilly and Company.